[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100502217":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":17,"responsibleParty":31,"collaborators":33,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":10,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":10,"enrollmentInfo":46,"targetDuration":10,"studyType":49,"phases":10,"briefSummary":50,"conditions":51,"keywords":10,"overallStatus":20,"whyStopped":10,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},{"fullName":5,"class":6},"Boehringer Ingelheim","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"All participants",null,"All participants must be diagnosed with rheumatic disease (connective tissue disease (CTD)) and interstitial lung disease (ILD) and fulfil all inclusion and no exclusion criteria. Information about participants will be obtained from electronic and physical medical records for existing data collection (over the past ten years, from 2012 to 2022) and\u002For from medical consultations for newly collected data (for the next three years, from 2023 to 2026). The participants' observation time varies and can be over the whole study duration (from 2012 to 2023), over the past ten years only (existing data) or over the next three years (new data).",[13],{"name":5,"role":14,"phone":15,"phoneExt":10,"email":16},"CONTACT","1-800-243-0127","clintriage.rdg@boehringer-ingelheim.com",[18],{"facility":19,"status":20,"city":21,"state":10,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":10},"Colegio Mexicano de Reumatologia","RECRUITING","Mexico City","04318","Mexico","MX",{"type":26,"coordinates":27},"Point",[28,29],-99.12766,19.42847,{"lat":29,"lon":28},{"type":32,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[34],{"name":35,"class":36},"TIC Social Mexico","UNKNOWN","100502217","connective-tissue-disease-associated-interstitial-lung-diseases-ctd-ild-epidemiology-non-interventional-study-nis-100502217",false,"NCT05819385","Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) Epidemiology Non-interventional Study (NIS)","Ambispective, Non-Interventional Study to Evaluate the Epidemiology of Interstitial Lung Diseases (ILDs) Associated to Rheumatic Diseases (Rheumatoid Arthritis, Connective Tissue Diseases, Spondylarthritis and Sarcoidosis) and the Progression Risk Factors in the Mexican Population","Inclusion Criteria:\n\nFor newly data collection:\n\n* Male and female Patients.\n* Patients over 18 years old.\n* Patient who gives his\u002Fher signed informed consent to be able to use information about their condition.\n* Patient who has the diagnosis of: rheumatoid arthritis, connective tissue disease (CTD) (systemic sclerosis or scleroderma; inflammatory myopathy: antisynthetase, dermatomyositis, polymyositis, mixed connective tissue disease; systemic lupus erythematosus; primary Sjögren syndrome; pulmonary fibrosis associated with non-specific autoimmunity; primary systemic vasculitis; psoriasis, anchylosing spondylitis, reactive arthritis) Spondyloarthritis (SpA) or sarcoidosis, (accordingly with the updated clinical criteria for each pathology).\n\nPatient with any interstitial lung diseases (ILD) diagnosed clinically and by a high-resolution computed tomography study with an interstitial pattern (supervised by an expert radiologist).\n\nFor existing data collection:\n\n* Medical Records from patients with whom contact was permanently lost for any reason since 2012 till the study start date.\n* Medical Records from male and female Patients.\n* Medical Records from patients over 18 years old.\n* Medical Records of patients that have at least: patient initials, date of birth, gender, date of diagnosis, full diagnosis of:\n\n  * Patient who has the diagnosis of: rheumatoid arthritis, CTD (systemic sclerosis or scleroderma; inflammatory myopathy: antisynthetase, dermatomyositis, polymyositis, mixed connective tissue disease; Systemic lupus erythematosus; primary Sjögren syndrome; pulmonary fibrosis associated with non-specific autoimmunity; primary systemic vasculitis; psoriasis, anchylosing spondylitis, reactive arthritis) SpA or Sarcoidosis, (accordingly with the updated clinical criteria for each pathology).\n  * Patient with any ILD diagnosed clinically and by a high-resolution computed tomography study with an interstitial pattern (supervised by an expert radiologist).\n\nExclusion Criteria:\n\n* Patient with a biopsy definition of usual interstitial pneumonitis, related to any other non-CTD.\n* Patient with post-chemotherapy or post-radiotherapy pneumonitis.\n* Medical Records of patients without full diagnostic of ILD (clinically and by biopsy or high-resolution computed tomography).","ALL","18 Years",{"count":47,"type":48},312,"ESTIMATED","OBSERVATIONAL","This study aims to characterize the epidemiology of interstitial lung diseases (ILD) associated to connective tissue disease (CTD) in Mexico, and to study its correlation with the different comorbidities and treatments used, as well as the possible impacts of these factors on the outcome of progression, exacerbations, and mortality in patients with ILD associated to CTD.",[52],"Lung Diseases, Interstitial","2026-05-04",{"date":55,"type":56},"2026-05-07","ACTUAL",{"date":58,"type":56},"2025-06-18",{"date":60,"type":48},"2027-12-01",{"name":5,"class":6},1]